Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

BACKGROUND: (V600)BRAF mutations drive approximately 50% of metastatic melanoma which can be therapeutically targeted by BRAF inhibitors (BRAFi) and, based on resistance mechanisms, the combination of BRAF and MEK inhibitors (BRAFi + MEKi). Although the combination therapy has been shown to provide...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Transl Med
Hoofdauteurs: Hernandez-Davies, Jenny E, Tran, Thai Q, Reid, Michael A, Rosales, Kimberly R, Lowman, Xazmin H, Pan, Min, Moriceau, Gatien, Yang, Ying, Wu, Jun, Lo, Roger S, Kong, Mei
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2015
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490757/
https://ncbi.nlm.nih.gov/pubmed/26139106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0581-2
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items